Results for the Combination of Nivolumab and Ibrutinib in Non-Hodgkin Lymphoma and CLL

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab and ibrutinib for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, discusses results from a trial studying the combination of nivolumab (Keytruda) and ibrutinib (Imbruvica) for the treatment of patients with relapsed non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL).

Data was first seen with this combination in preclinical studies with mouse models of lymphomas and solid tumors. These exciting results have since been replicated in a number of trials. This trial specifically looked at subsets of patients with follicular lymphoma, diffuse large B-cell lymphoma, high-risk chronic lymphocytic leukemia, and Richter's transformation.

While the combination seems safe and can be administered in full doses within these subsets, the results from the Richter's transformation group stand out the most. The data in other subsets is no better or worse than in treatments with ibrutinib alone, but the Richter's transformation group displayed higher response rates with the combination than treatments with ibutinib as a single agent.